

# Bakhos A Tannous

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/986839/publications.pdf>

Version: 2024-02-01

107  
papers

11,946  
citations

57758

44  
h-index

33894

99  
g-index

111  
all docs

111  
docs citations

111  
times ranked

22680  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune Checkpoint Inhibition in GBM Primed with Radiation by Engineered Extracellular Vesicles. ACS Nano, 2022, 16, 1940-1953.	14.6	58
2	Abstract LB168: Platelet RNA signature enables early and accurate detection of ovarian cancer: An intercontinental, biomarker identification study. Cancer Research, 2022, 82, LB168-LB168.	0.9	1
3	Abstract LB507: Towards elucidating the role of RNA modifications in cancer by improving the quantitative accuracy of mass spectrometric profiling of RNA modifications. Cancer Research, 2022, 82, LB507-LB507.	0.9	0
4	Sustained subcutaneous delivery of secretome of human cardiac stem cells promotes cardiac repair following myocardial infarction. Cardiovascular Research, 2021, 117, 918-929.	3.8	43
5	Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin. Science Advances, 2021, 7, .	10.3	17
6	Targeted delivery of neural progenitor cell-derived extracellular vesicles for anti-inflammation after cerebral ischemia. Theranostics, 2021, 11, 6507-6521.	10.0	104
7	Promoting Women in Academic Medicine during COVID-19 and Beyond. Journal of General Internal Medicine, 2021, 36, 3292-3294.	2.6	3
8	Abstract 3114: Olfactory ensheathing glia as a cell-based therapy for glioblastomas. , 2021, , .		0
9	BSCI-16. Olfactory receptor 5B21 drives breast cancer metastasis. Neuro-Oncology Advances, 2021, 3, iii4-iii4.	0.7	0
10	Olfactory receptor 5B21 drives breast cancer metastasis. IScience, 2021, 24, 103519.	4.1	4
11	TAMI-46. FRIEND AND FOE: RADIATION THERAPY INCREASES GLIOBLASTOMA IMMUNE EVASION VIA EVS. Neuro-Oncology, 2021, 23, vi208-vi208.	1.2	0
12	The natural compound obtusaquinone targets pediatric high-grade gliomas through ROS-mediated ER stress. Neuro-Oncology Advances, 2020, 2, vdaa106.	0.7	2
13	Tumor-Educated Platelet RNA for the Detection and (Pseudo)progression Monitoring of Glioblastoma. Cell Reports Medicine, 2020, 1, 100101.	6.5	52
14	Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance. Advanced Science, 2020, 7, 2002015.	11.2	25
15	Regulatory T cells engineered with TCR signalingâ€responsive IL-2 nanogels suppress alloimmunity in sites of antigen encounter. Science Translational Medicine, 2020, 12, .	12.4	39
16	Small but Fierce: Tracking the Role of Extracellular Vesicles in Glioblastoma Progression and Therapeutic Resistance. Advanced Biology, 2020, 4, 2000035.	3.0	3
17	CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent. Pharmacological Research, 2020, 159, 105010.	7.1	61
18	Extracellular Vesicles Induce Mesenchymal Transition and Therapeutic Resistance in Glioblastomas through NFâ€B/STAT3 Signaling. Advanced Biology, 2020, 4, 1900312.	3.0	15

#	ARTICLE	IF	CITATIONS
19	Obtusaquinone: A Cysteine-Modifying Compound That Targets Keap1 for Degradation. ACS Chemical Biology, 2020, 15, 1445-1454.	3.4	18
20	Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasisâ€œInitiating Cells. Molecular Cancer Therapeutics, 2020, 19, 1134-1147.	4.1	17
21	STEM-15. SMALL BUT FIERCE: THE ROLE OF EXTRACELLULAR VESICLES IN MESENCHYMAL TRANSITION AND THERAPEUTIC RESISTANCE IN GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii199-ii199.	1.2	0
22	THER-03. REPURPOSING MEFLOROQUINE AND ANALOGUES FOR DIPG THERAPY. Neuro-Oncology, 2019, 21, ii114-ii114.	1.2	0
23	An allosteric inhibitor of SHP2 effectively targets PDGFRÎ±-driven glioblastoma. Neuro-Oncology, 2019, 21, 1348-1349.	1.2	4
24	Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1. Molecular Therapy - Methods and Clinical Development, 2019, 15, 18-26.	4.1	17
25	Patient-Derived Glioma Models: From Patients to Dish to Animals. Cells, 2019, 8, 1177.	4.1	86
26	THER-04. OLFACTORY ENSHEATHING CELLS TRAVEL THEIR NATURE ROUTE FROM NASAL CAVITY TO CNS AND DELIVER THERAPEUTIC TRANSGENES TO HIGH-GRADE PEDIATRIC GLIOMAS. Neuro-Oncology, 2019, 21, ii114-ii115.	1.2	0
27	A TNF-NF-Î²-STAT3 loop triggers resistance of glioma-stem-like cells to Smac mimetics while sensitizing to EZH2 inhibitors. Cell Death and Disease, 2019, 10, 268.	6.3	8
28	Radiation-Induced Targeted Nanoparticle-Based Gene Delivery for Brain Tumor Therapy. ACS Nano, 2019, 13, 4028-4040.	14.6	147
29	Sustained NF-Î²B-STAT3 signaling promotes resistance to Smac mimetics in Glioma stem-like cells but creates a vulnerability to EZH2 inhibition. Cell Death Discovery, 2019, 5, 72.	4.7	18
30	Methods for Systematic Identification of Membrane Proteins for Specific Capture of Cancer-Derived Extracellular Vesicles. Cell Reports, 2019, 27, 255-268.e6.	6.4	38
31	Phenotypic Plasticity of Invasive Edge Glioma Stem-like Cells in Response to Ionizing Radiation. Cell Reports, 2019, 26, 1893-1905.e7.	6.4	161
32	Membrane-bound Gaussia luciferase as a tool to track shedding of membrane proteins from the surface of extracellular vesicles. Scientific Reports, 2019, 9, 17387.	3.3	17
33	Olfactory Ensheathing Cells: A Trojan Horse for Glioma Gene Therapy. Journal of the National Cancer Institute, 2019, 111, 283-291.	6.3	22
34	Olfactory ensheathing cells travel their natural nasal pathway to deliver therapeutics to brain tumors. Oncotarget, 2019, 10, 4351-4353.	1.8	1
35	Activity-Independent Effects of CREB on Neuronal Survival and Differentiation during Mouse Cerebral Cortex Development. Cerebral Cortex, 2018, 28, 538-548.	2.9	45
36	Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8. Journal of Extracellular Vesicles, 2018, 7, 1446660.	12.2	64

#	ARTICLE	IF	CITATIONS
37	Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. <i>Neuro-Oncology</i> , 2018, 20, 642-654.	1.2	39
38	Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. <i>Biomaterials</i> , 2018, 150, 137-149.	11.4	739
39	Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. <i>Neuro-Oncology</i> , 2017, 19, now253.	1.2	35
40	Bidirectional Anticipation of Future Osmotic Challenges by Vasopressin Neurons. <i>Neuron</i> , 2017, 93, 57-65.	8.1	63
41	Integrated Kidney Exosome Analysis for the Detection of Kidney Transplant Rejection. <i>ACS Nano</i> , 2017, 11, 11041-11046.	14.6	106
42	Secreted Reporters for Monitoring Multiple Promoter Function. <i>Methods in Molecular Biology</i> , 2017, 1651, 33-47.	0.9	3
43	Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets. <i>Cancer Cell</i> , 2017, 32, 238-252.e9.	16.8	235
44	Optical clearing and fluorescence deep-tissue imaging for 3D quantitative analysis of the brain tumor microenvironment. <i>Angiogenesis</i> , 2017, 20, 533-546.	7.2	71
45	Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. <i>Oncotarget</i> , 2016, 7, 1066-1075.	1.8	172
46	Therapeutic potential of targeting micro RNA in established intracranial glioblastoma: first steps toward the clinic. <i>EMBO Molecular Medicine</i> , 2016, 8, 268-287.	6.9	117
47	Imaging Tumor Vascularity and Response to Anti-Angiogenic Therapy Using Gaussia Luciferase. <i>Scientific Reports</i> , 2016, 6, 26353.	3.3	1
48	Dynamic GABAergic afferent modulation of AgRP neurons. <i>Nature Neuroscience</i> , 2016, 19, 1628-1635.	14.8	165
49	Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16017.	4.4	21
50	Synthesis and evaluation of N-(methylthiophenyl)picolinamide derivatives as PET radioligands for metabotropic glutamate receptor subtype 4. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 133-139.	2.2	13
51	Re: a Word of Caution on New and Revolutionary Diagnostic Tests. <i>Cancer Cell</i> , 2016, 29, 143-144.	16.8	4
52	Intracranial AAV9-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma. <i>Molecular Oncology</i> , 2016, 10, 625-634.	4.6	18
53	Multimodal targeted high relaxivity thermosensitive liposome for in vivo imaging. <i>Scientific Reports</i> , 2015, 5, 17220.	3.3	18
54	ATPS-84HYDROXYUREA SENSITIZES PATIENT-DERIVED GLIOBLASTOMA TUMORS TO TEMOZOLOMIDE IRRESPECTIVE OF MGMT STATUS. <i>Neuro-Oncology</i> , 2015, 17, v37.1-v37.	1.2	0

#	ARTICLE	IF	CITATIONS
55	Heparin affinity purification of extracellular vesicles. Scientific Reports, 2015, 5, 10266.	3.3	152
56	CBM-16TUMOR-EDUCATED PLATELET-BASED LIQUID BIOPSIES IN GLIOBLASTOMA PATIENTS. Neuro-Oncology, 2015, 17, v72.3-v72.	1.2	1
57	A neural basis for melanocortin-4 receptor-regulated appetite. Nature Neuroscience, 2015, 18, 863-871.	14.8	324
58	Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nature Communications, 2015, 6, 7029.	12.8	449
59	RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell, 2015, 28, 666-676.	16.8	700
60	Co-operative binding assay for the characterization of mGlu4 allosteric modulators. Neuropharmacology, 2015, 97, 142-148.	4.1	10
61	Pharmacokinetics of Natural and Engineered Secreted Factors Delivered by Mesenchymal Stromal Cells. PLoS ONE, 2014, 9, e89882.	2.5	31
62	Noninvasive In Vivo Monitoring of Extracellular Vesicles. Methods in Molecular Biology, 2014, 1098, 249-258.	0.9	39
63	Dynamic Biodistribution of Extracellular Vesicles <i>in Vivo</i> Using a Multimodal Imaging Reporter. ACS Nano, 2014, 8, 483-494.	14.6	663
64	Systemic Anticancer Neural Stem Cells in Combination with a Cardiac Glycoside for Glioblastoma Therapy. Stem Cells, 2014, 32, 2021-2032.	3.2	18
65	Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer. Journal of Extracellular Vesicles, 2014, 3, 25657.	12.2	29
66	Simultaneous In Vivo Monitoring of Regulatory and Effector T Lymphocytes Using Secreted Gaussia Luciferase, Firefly Luciferase, and Secreted Alkaline Phosphatase. Methods in Molecular Biology, 2014, 1098, 211-227.	0.9	6
67	Gaussia Luciferase-Based Mycoplasma Detection Assay in Mammalian Cell Culture. Methods in Molecular Biology, 2014, 1098, 47-55.	0.9	3
68	EFEMP1 induces $\beta$ -secretase/Notch-mediated temozolomide resistance in glioblastoma. Oncotarget, 2014, 5, 363-374.	1.8	41
69	Mouse Gender Influences Brain Transduction by Intravascularly Administered AAV9. Molecular Therapy, 2013, 21, 1470-1471.	8.2	33
70	Advances in stem cell therapy against gliomas. Trends in Molecular Medicine, 2013, 19, 281-291.	6.7	47
71	Directed Molecular Evolution Reveals Gaussia Luciferase Variants with Enhanced Light Output Stability. Analytical Chemistry, 2013, 85, 3006-3012.	6.5	33
72	Multiplex Blood Reporters for Simultaneous Monitoring of Cellular Processes. Analytical Chemistry, 2013, 85, 10205-10210.	6.5	10

#	ARTICLE	IF	CITATIONS
73	Functional multiplex reporter assay using tagged Gaussia luciferase. Scientific Reports, 2013, 3, 1046.	3.3	14
74	Effects of the Selective MPS1 Inhibitor MPS1-IN-3 on Glioblastoma Sensitivity to Antimitotic Drugs. Journal of the National Cancer Institute, 2013, 105, 1322-1331.	6.3	94
75	Triple Bioluminescence Imaging for In Vivo Monitoring of Cellular Processes. Molecular Therapy - Nucleic Acids, 2013, 2, e99.	5.1	77
76	Targeting Cancer Cells With the Natural Compound Obtusaquinone. Journal of the National Cancer Institute, 2013, 105, 643-653.	6.3	19
77	A Water-Soluble Coelenterazine for Sensitive In Vivo Imaging of Coelenterate Luciferases. Molecular Therapy, 2012, 20, 692-693.	8.2	27
78	Single Reporter for Targeted Multimodal in Vivo Imaging. Journal of the American Chemical Society, 2012, 134, 5149-5156.	13.7	45
79	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
80	Enhanced <i>Gaussia</i> Luciferase Blood Assay for Monitoring of in Vivo Biological Processes. Analytical Chemistry, 2012, 84, 1189-1192.	6.5	16
81	Microvesicle-associated AAV Vector as a Novel Gene Delivery System. Molecular Therapy, 2012, 20, 960-971.	8.2	236
82	Sensitive Assay for Mycoplasma Detection in Mammalian Cell Culture. Analytical Chemistry, 2012, 84, 4227-4232.	6.5	17
83	Codon-Optimized <i>Luciola Italica</i> Luciferase Variants for Mammalian Gene Expression in Culture and in Vivo. Molecular Imaging, 2012, 11, 7290.2011.00022.	1.4	12
84	Multimodal In Vivo Imaging and Blood Monitoring of Intrinsic and Extrinsic Apoptosis. Molecular Therapy, 2011, 19, 1090-1096.	8.2	37
85	Bioluminescence imaging: progress and applications. Trends in Biotechnology, 2011, 29, 624-633.	9.3	240
86	Secreted blood reporters: Insights and applications. Biotechnology Advances, 2011, 29, 997-1003.	11.7	148
87	TorsinA participates in endoplasmic reticulum-associated degradation. Nature Communications, 2011, 2, 393.	12.8	99
88	Functional Drug Screening Assay Reveals Potential Glioma Therapeutics. Assay and Drug Development Technologies, 2011, 9, 281-289.	1.2	31
89	Measurement of Fluoride-Induced Endoplasmic Reticulum Stress Using Gaussia Luciferase. Methods in Enzymology, 2011, 491, 111-125.	1.0	6
90	Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor- $\alpha$ -related apoptosis-inducing ligand and induces an alternative cell death pathway. Neuro-Oncology, 2011, 13, 1213-1224.	1.2	52

#	ARTICLE	IF	CITATIONS
91	The Acid Test of Fluoride: How pH Modulates Toxicity. PLoS ONE, 2010, 5, e10895.	2.5	49
92	Tannous et al. Respond:. Molecular Therapy, 2009, 17, 1311-1312.	8.2	1
93	Real-Time Monitoring of Nuclear Factor $\kappa$ B Activity in Cultured Cells and in Animal Models. Molecular Imaging, 2009, 8, 7290.2009.00026.	1.4	56
94	Secreted Gaussia Luciferase as a Biomarker for Monitoring Tumor Progression and Treatment Response of Systemic Metastases. PLoS ONE, 2009, 4, e8316.	2.5	79
95	Mutant Sodium Channel for Tumor Therapy. Molecular Therapy, 2009, 17, 810-819.	8.2	18
96	Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nature Protocols, 2009, 4, 582-591.	12.0	245
97	Gaussia Luciferase Variant for High-Throughput Functional Screening Applications. Analytical Chemistry, 2009, 81, 7102-7106.	6.5	74
98	Comparison of conventional guaiac to four immunochemical methods for fecal occult blood testing: Implications for clinical practice in hospital and outpatient settings. Clinica Chimica Acta, 2009, 400, 120-122.	1.1	22
99	Downregulated MicroRNA-200a in Meningiomas Promotes Tumor Growth by Reducing E-Cadherin and Activating the Wnt/ $\beta$ 2-Catenin Signaling Pathway. Molecular and Cellular Biology, 2009, 29, 5923-5940.	2.3	240
100	Real-time monitoring of nuclear factor $\kappa$ B activity in cultured cells and in animal models. Molecular Imaging, 2009, 8, 278-90.	1.4	49
101	A secreted luciferase for ex vivo monitoring of in vivo processes. Nature Methods, 2008, 5, 171-173.	19.0	263
102	siRNA knock-down of mutant torsinA restores processing through secretory pathway in DYT1 dystonia cells. Human Molecular Genetics, 2008, 17, 1436-1445.	2.9	63
103	Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cells. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 7271-7276.	7.1	127
104	A Highly Sensitive Assay for Monitoring the Secretory Pathway and ER Stress. PLoS ONE, 2007, 2, e571.	2.5	123
105	Metabolic biotinylation of cell surface receptors for in vivo imaging. Nature Methods, 2006, 3, 391-396.	19.0	105
106	Codon-Optimized Gaussia Luciferase cDNA for Mammalian Gene Expression in Culture and in Vivo. Molecular Therapy, 2005, 11, 435-443.	8.2	635
107	T7 RNA polymerase as a self-replicating label for antigen quantification. Nucleic Acids Research, 2002, 30, 140e-140.	14.5	6